Finding myself with a lengthy layover at the Dublin Airport in Swords, Ireland, on my way to New York from BIO-Europe (and with a surprising lack of Guinness at the…
Poor Louie... Poor Louie King Louis XI of France (1423-1483) was an interesting character. At 17, he rebelled against his Father, Charles VII. Later forgiven by papa, he ascended to the…
In almost every out-licensing or investor presentation we see, there is likely a slide that shows the “Total Addressable Market” (TAM). And, it is always a very large number. The…
In July, 2025, GSK (UK) and Hengrui Pharmaceutical (China) executed a $12 billion license and option agreement valued at $12 billion, with $500 million paid upfront. The press release is…
I. Introduction In our industry, not all companies are built for, or even aspire to, worldwide reach. Many are geographically limited, with commercial operations confined to a single country (such…
Introduction One of the benefits of having BIO in Boston is that it provides me with a ~3.5 hour drive back to New York. This gives me a chance to…
https://youtu.be/ryfz4zM6RJA Our Annual Year in Review Video - 2024 Edition At long last, here is our Annual Year in Review video - 2024 Edition. In this video, we cover: FDA…
Join us on Sunday prior to BIO-Europe Our annual Pre-BIO-Europe BYO primer will be held at O'Leary's on Sunday, November 3 at 5 pm (or, 1700, if you prefer).O'Leary's is located…
How much does it cost to develop a drug?We still don't know. The most recent analysis on this subject was published earlier this year. In an excellent analysis, Sertkaya et al. analyzed…
This article was triggered by a beverage-induced discussion I had with Martin Eglitis at BIO-Europe earlier this month. In my licensing courses, I spend a bit of time talking about the probability…